These results not only revealed the contribution of conventional TLR4-based immunotherapeutic activities in the present study but also highlighted its potent antitumor effect through cooperative cGAS-STING activation, substantiating the immunostimulatory capability of the BSA-Man@Mn2+-Ft@Lap nanoagonist to induce robust tumor-specific T cell immunity in vitro. This evidence concerns the gene TLR4 and neoplasm.